Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

One reason why many investors could be asking this question is Pfizer's high dividend payout ratio of 99.4%. This metric ...

Its March 20 $29 put had the highest unusual options activity on the day with a Vol/OI (volume-to-open-interest) ratio of 210 ...

Investing $12,000 in the stock today would allow you to collect approximately $600 in dividends per year. Combined with the ...

Pfizer Inc. (NYSE:PFE) ranks among the best stocks under $25 to buy now. Citing the company’s cautious 2026 outlook, BMO ...

Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells ...

Pfizer shares are trading in the mid-$20s as investors grapple with a critical question: is this battered pharmaceutical giant destined to remain stuck in neutral, or does its aggressive push into ...